First Time Loading...

Advance Residence Investment Corp
TSE:3269

Watchlist Manager
Advance Residence Investment Corp Logo
Advance Residence Investment Corp
TSE:3269
Watchlist
Price: 338 000 JPY 1.5%
Updated: Apr 29, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

480.6B
+2%
Assets
Growth Rates:
1 Year
+2%
3 Years
+5%
5 Years
+6%
7 Years
+7%
10 Years
+15%
234.5B
-3%
Liabilities
Growth Rates:
1 Year
-2%
3 Years
+3%
5 Years
+1%
7 Years
+2%
10 Years
+5%
246.1B
+7%
Equity
Growth Rates:
1 Year
+6%
3 Years
+7%
5 Years
+12%
7 Years
+11%
10 Years
+26%

Balance Sheet Decomposition
Advance Residence Investment Corp

480.6B
Assets
234.5B
Liabilities
480.6B
Assets
234.5B
Liabilities
Current Assets 28.3B
Cash & Short-Term Investments 17.5B
Receivables 141.1m
Other Current Assets 10.6B
Non-Current Assets 452.3B
Long-Term Investments 298.3B
PP&E 148.9B
Intangibles 1.6B
Other Non-Current Assets 3.5B
Current Liabilities 29.7B
Accounts Payable 593.8m
Accrued Liabilities 84.1m
Short-Term Debt 5B
Other Current Liabilities 24B
Non-Current Liabilities 204.8B
Long-Term Debt 200.2B
Other Non-Current Liabilities 4.7B

Balance Sheet
Advance Residence Investment Corp

Rotate your device to view
Balance Sheet
Currency: JPY
Jul-2014 Jul-2015 Jul-2016 Jul-2017 Jul-2018 Jul-2019 Jul-2020 Jul-2021 Jul-2022 Jul-2023
Assets
Cash & Cash Equivalents
7 593
9 880
16 505
12 990
13 742
14 777
14 179
14 730
13 776
17 666
Cash Equivalents
7 593
9 880
16 505
12 990
13 742
14 777
14 179
14 730
13 776
17 666
Short-Term Investments
8 000
5 850
0
0
0
0
0
0
0
0
Total Receivables
256
256
194
188
203
189
215
156
135
144
Accounts Receivables
256
256
194
188
203
189
215
156
135
144
Other Receivables
0
0
0
0
0
0
0
0
0
0
Other Current Assets
8 612
9 117
9 745
10 090
10 100
10 194
10 361
10 272
10 480
10 519
Total Current Assets
24 461
25 103
26 444
23 267
24 044
25 160
24 754
25 159
24 390
28 330
PP&E Net
139 911
134 204
135 267
133 965
138 048
137 607
141 645
141 095
146 385
148 813
PP&E Gross
139 911
134 204
135 267
133 965
138 048
137 607
141 645
141 095
146 385
148 813
Accumulated Depreciation
7 360
8 734
10 447
12 196
13 790
15 628
17 364
19 320
21 350
24 039
Intangible Assets
2 793
3 254
3 185
3 116
1 975
1 911
1 842
1 772
1 702
1 632
Long-Term Investments
265 655
275 939
280 780
287 631
286 241
284 430
286 708
287 169
289 613
289 028
Other Long-Term Assets
2 394
2 492
2 483
2 500
2 538
2 481
2 620
2 635
2 807
3 485
Total Assets
435 215
N/A
440 991
+1%
448 160
+2%
450 479
+1%
452 846
+1%
451 590
0%
457 569
+1%
457 829
+0%
464 898
+2%
471 288
+1%
Liabilities
Accounts Payable
219
355
343
299
337
253
326
543
489
735
Accrued Liabilities
201
164
213
140
135
105
120
82
95
128
Short-Term Debt
0
0
0
0
1 000
2 000
2 000
500
1 000
3 000
Current Portion of Long-Term Debt
23 448
27 733
36 500
33 446
23 460
24 870
26 718
27 220
21 230
24 000
Other Current Liabilities
1 326
1 364
1 398
1 430
1 472
1 482
1 593
1 552
1 603
1 692
Total Current Liabilities
25 195
29 616
38 454
35 314
26 405
28 710
30 757
29 896
24 417
29 555
Long-Term Debt
198 347
199 754
197 364
189 928
201 458
198 448
190 870
192 789
205 579
206 309
Other Liabilities
3 916
3 967
4 426
4 482
4 459
4 595
4 716
4 652
4 648
4 640
Total Liabilities
227 457
N/A
233 338
+3%
240 244
+3%
229 725
-4%
232 322
+1%
231 753
0%
226 343
-2%
227 337
+0%
234 644
+3%
240 504
+2%
Equity
Common Stock
114 937
114 937
114 937
127 690
127 690
127 690
139 035
139 035
139 035
139 035
Retained Earnings
92 821
92 717
92 979
93 064
92 837
92 172
92 224
91 507
91 104
91 016
Other Equity
0
0
0
0
3
25
33
50
115
733
Total Equity
207 758
N/A
207 654
0%
207 916
+0%
220 755
+6%
220 524
0%
219 837
0%
231 226
+5%
230 492
0%
230 254
0%
230 784
+0%
Total Liabilities & Equity
435 215
N/A
440 991
+1%
448 160
+2%
450 479
+1%
452 846
+1%
451 590
0%
457 569
+1%
457 829
+0%
464 898
+2%
471 288
+1%
Shares Outstanding
Common Shares Outstanding
1
1
1
1
1
1
1
1
1
1

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 132,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.